期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

胃酸分泌抑制剂相互作用研究进展 被引量：16

暂未订购
导出
摘要 胃酸分泌抑制剂即抑酸剂，包括H2受体阻断剂（ histamine-receptor antagonists, H2RA,如西咪替丁、雷尼替丁、法莫替丁、尼扎替丁）、质子泵抑制剂（protonp ump inhibitors，PPI，如奥美拉唑、兰索拉唑、泮托拉唑、雷贝拉唑、埃索美拉唑）。其除作为治疗上消化道疾病、预防应激l生溃疡的一线药物外，还可用于化疗止吐、预防非甾体抗炎药相关『生溃疡及使用激素时护胃，可治疗幽门螺杆菌感染及改善心肌梗死或冠状动脉介入支架术后长期服用抗血小板药（氯吡格雷、阿司匹林）引起的胃食管反流症状”。
作者 罗密 郑丽云 刘节君 叶燕嫦 欧志坚
机构地区 佛山市妇幼保健院药剂科
出处 《中国医院用药评价与分析》 2014年第1期94-96,共3页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 胃酸分泌抑制剂 相互作用 ANTAGONISTS H2受体阻断剂 幽门螺杆菌感染 胃食管反流症状 质子泵抑制剂 上消化道疾病
分类号 R975 [医药卫生—药品]
  • 相关文献

参考文献19

  • 1Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thieno- pyridines : a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastroin- testinal risks of antiplatelet therapy and NSAID use [ J ]. Am J Gastroenterol,2010,105 (12) :2533-2549.
  • 2Budha NR, Frymoyer A, Smelick GS, et al. Drug absorption interactions between oral targeted anticancer agents and PPIs:is pH-dependent solubility the Achilles heel of targeted therapy? [ J ]. Clin Pharmacol Ther, 2012,92(2) :203-213.
  • 3Walravens J,Brouwers J, Sprier I,et al. Effect of pH and comedication on gastrointestinal absorption of posaco- nazole: monitoring of intraluminal and plasma drug concentrations [ J ~. Clin Pharmacokinet, 2011,50 ( 11 ) : 725-734.
  • 4Budha NR, Frymoyer A, Smelick GS, et al. Drug absorption interactions between oral targeted anticancer agents and PPIs:is pH-dependent solubility the Achilles heel of targeted therapy? [ J 1. Clin Pharmacol Ther, 2012,92(2) :203-213.
  • 5Johnson MD, Hamilton CD, Drew RH,et al. A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution [ J ]. J Antimicrob Chemother ,2003,51 ( 2 ) :453-457.
  • 6陈新谦,金有豫,汤光.新编药物学[M].17版.北京:人民卫生出版社,2011:3465.
  • 7Ogawa R, Echizen H. Drug-drug interaction profiles of proton pump inhibitors [ J ]. Clin Pharmacokinet, 2010,49 (8) :509-533.
  • 8Zvyaga T, Chang SY, Chen C, et al. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450:focus on cytochrome P450 2C19 [ J]. Drug Metab Dispos,2012,40( 9 ) :1698-1711.
  • 9Choi YH, Lee U, Suh JH, et al. Pharmacokinetic interaction between acetamidocaproic acid ( AACA ~ and cimetidine in indomethacin-induced acute gastric ulcer and control rats:inhibition of active renal secretion of AACA by cimetidine [ J ]. Xenobiotica, 2011,41 ( 5 ) : 409- 415.
  • 10Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thieno- pyridines : a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastroin- testinal risks of antiplatelet therapy and NSAID use [ J ]. Am J Gastroenterol,2010.105 (12) :2533-2549.

二级参考文献12

  • 1Patrono C,Bachmann F,Baigent C,et al.Expert consensus document on the use of antiplatelet agents.The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology.Eur Heart J,2004,25:166-181.
  • 2Niv Y,Battler A,Abuksis G,et al.Endoscopy in asymptomatic minidose aspirin consumers.Dig Dis Sci,2005,50:78-80.
  • 3Silverstein FE,Graham DY,Senior JR,et al.Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs.A randomized,double-blind,placebo-controlled trial.Ann Intern Med,1995,123:241-249.
  • 4Huang JQ,Sridhar S,Hunt RH.Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in pepticulcer disease:a recta-analysis.Lancet,2002,359:14-22.
  • 5Lanas A,Scheiman J.Low-dose aspirin and upper gastrointestinal damage:epidemiology,prevention and treatment.Curr Med Res Opin,2007,23:163-173.
  • 6Inoue M, Okada H, Hori S, et al. Does pretreatment with lansoprazolc infuence Helicobacter pylori eradication rate and quality of life? [J]. Digestion, 2010, 81(4) :218.
  • 7Spencer CM, Faulds D. Lansoprazole. A reappraisal of its phannacodynamie and pharmacokinefie properties, and its therapeutic efficacy in acid-related disorders[J]. Drugs, 1994, 48(3):404.
  • 8Pearce RE, Rodrigues AD, Goldstein JA, et al. Identification of the human P450 enzymes involved in lansoprazole metabolism[J]. J Pharmacol Exp Ther, 1996, 277(2) :805.
  • 9Saito M, Yasui-Furukori N, Uno T, et al. Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genlotypes [ J ]. Br J Clin Pharmacol, 2005, 59(3) :302.
  • 10Kita T, Baba T, Aoymna N, et al. Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors[J]. Biol Pharm Bull, 2003, 26(3):386.

共引文献845

同被引文献161

引证文献16

二级引证文献88

中国医院用药评价与分析
2014年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部